Mesoblast director Eric Rose exercises options, adjusts shareholding

Eric Rose, a director at Mesoblast Limited, increased his direct holding of ordinary shares by 120,000 through the exercise of options on October 8, 2025. These options were due to expire by November 29, 2025. The exercise incurred a cost of $157,200 for the acquisition of these shares.

Concurrently with the option exercise, Rose sold 120,000 ordinary shares on-market, generating $352,800. This sale was primarily conducted to fund the exercise price of the options and cover the director's tax liability associated with the option exercise for the tax year ending December 31, 2025.

Following these transactions, Rose's total direct holdings now include 6,107,293 ordinary shares, which incorporate 71,472 American Depositary Shares, and 6,874,102 options.